NEO

Neogenomics Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↓ 1/10
  • Value↓ 1/10
Neogenomics sales and earnings growth
NEO Growth
Low
  • Revenue Y/Y↑ 9.79%
  • EPS Y/Y↓ -24.59%
  • FCF Y/Y↑ 84.28%
Neogenomics gross and profit margin trends
NEO Profitability
Neutral
  • Gross margin ↑ 43.20%
  • EPS margin↓ -13.30%
  • ROIC 5Y↓ -11.07%
Neogenomics net debt vs free cash flow
NEO Risk
Great
  • Debt / Equity↓ 0.5
  • Debt / FCF↑ 51.6
  • Interest coverage↓ -36.4

Neogenomics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Diagnostics & Research stocks